NCT06110338View on ClinicalTrials.gov

Safety and Tolerance Study of IBI355 in Health Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

September 20, 2024

Study Completion Date

September 23, 2024

Conditions
Healthy Subjects
Interventions
DRUG

placebo

placebo iv. once.

DRUG

IBI355

IBI355 iv. once.

Trial Locations (1)

100049

Aerospace Center Hospital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06110338 - Safety and Tolerance Study of IBI355 in Health Volunteers | Biotech Hunter | Biotech Hunter